Prevention and treatment of factor VIII inhibitors in murine hemophilia A

Blood

Volumn 95, Issue 4, 2000, Pages 1324-1329

  Qian, Jiahua ^b   Collins, Mary ^b   Sharpe, Arlene H ^b   Hoyer, Leon W ^a  

^a HOLLAND LABORATORY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE THERAPY; HEMOPHILIA A; MALE; MOUSE; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; SUBSTITUTION THERAPY; T LYMPHOCYTE ACTIVATION;

EID: 0034651552     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1324.004k25_1324_1329     Document Type: Article

References (33)

1. Hoyer LW. Hemophilia A. N Engl J Med. 1994; 330:38.
2. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, eds. Inhibitors to Coagulation Factors. New York, NY: Plenum; 1995:35.
3. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996;88:3846.
4. Kung S-H, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998;91:784.
5. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics. 1995;10:119.
6. Qian J, Borovok M, Bi L, Kazazian HH, Hoyer L. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost. 1999;81:240.
7. Connelly S, Andrews JL, Gallo AM. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91:3273.
8. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A. 1998;95:5734.
9. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 1996;14:233.
10. Tivol EA, Borriello F, Schweitzer AN, Lynch W, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3:541.
11. Waterhouse P, Penninger J, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995; 270:985.
12. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD2B/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83: 3815.
13. Linsley PS, Wallace PM, Johnson J. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257:792.
14. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1999;165:231.
15. Abrams JR, Lebwohl MG, Guuzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243.
16. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340: 1704.
17. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996;88:3446.
18. Borriello F, Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997;6:303.
19. Streurer, W. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol. 1995;155:1165.
20. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83:3536.
21. Lollar P, Parker ET, Curtis JE. et al. Inhibition of factor VIIIa by human anti-A2 subunit antibodies. J Clin Invest. 1994;93:2497.
22. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb et Diath Haem. 1975;34:875.
23. Freeman GJ, Borriello F, Hodes RJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science. 1993; 262:907.
24. Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley PS. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J Immunol. 1999;154:5885.
25. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med. 1994; 179:1127.
26. Schwartz RS. The new immunology - the end of immunosuppressive drug therapy? N Engl J Med. 1999;340:1754.
27. Sayegh MH. Finally, CTLA4Ig graduates to the clinic. J Clin Invest. 1999;103:1223.
28. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302.
29. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 1995;80:707.
30. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995;181:1145.
31. Vyth-Dreese FA, Dellemijn TA, Majoor D, de Jong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol. 1995;25:3023.
32. Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol. 1995; 155:556.
33. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood. 1996; 87:4671.